Julie Clark

2021

In 2021, Julie Clark earned a total compensation of $2.4M as Former Chief Medical Officer at Avalanche Biotechnologies.

Compensation breakdown

Option Awards$1,418,109
Salary$405,220
Stock Awards$574,130
Other$7,847
Total$2,405,306

Clark received $1.4M in option awards, accounting for 59% of the total pay in 2021.

Clark also received $405.2K in salary, $574.1K in stock awards and $7.8K in other compensation.

Rankings

In 2021, Julie Clark's compensation ranked 5,309th out of 12,415 executives tracked by ExecPay. In other words, Clark earned more than 57.2% of executives.

ClassificationRankingPercentile
All
5,309
out of 12,415
57th
Division
Manufacturing
2,233
out of 5,505
59th
Major group
Chemicals And Allied Products
973
out of 2,375
59th
Industry group
Drugs
867
out of 2,096
59th
Industry
Biological Products, Except Diagnostic Substances
212
out of 449
53rd

Pay ratio

Julie Clark's Pay$2,405,306
Median Employee's Pay$188,229
Pay Ratio

13

to 1

In 2021, the annual total compensation of Julie Clark was $2,405,306.

The annual total compensation of the median employee at Avalanche Biotechnologies was $188,229.

The ratio of Julie Clark's pay to the pay of median employee was therefore 13 to one.

Source: SEC filing on April 26, 2022.

Clark's colleagues

We found nine more compensation records of executives who worked with Julie Clark at Avalanche Biotechnologies in 2021.

2021

Laurent Fischer

Avalanche Biotechnologies

Chief Executive Officer

2021

Christopher DeRespino

Avalanche Biotechnologies

Chief Financial Officer

2021

Angela Thedinga

Avalanche Biotechnologies

Chief Technology Officer

2021

Leone Patterson

Avalanche Biotechnologies

Chief Financial Officer

2021

Kishor Soparkar

Avalanche Biotechnologies

Chief Operating Officer

2021

Brigit Riley

Avalanche Biotechnologies

Chief Scientific Officer

2021

Rupert D'Souza

Avalanche Biotechnologies

Chief Financial Officer

2021

Thomas Leung

Avalanche Biotechnologies

Chief Financial Officer

2021

Jack Thrift

Avalanche Biotechnologies

Chief Financial Officer

News

In-depth

You may also like